Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.

Literature DB >> 3221222

The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.

J H Coakley¹, J Moorcraft, L J Hipkin, C S Smith, R D Griffiths, R H Edwards.

Abstract

Mazindol has been reported to improve muscle function in Duchenne muscular dystrophy (DMD) by virtue of its growth hormone (GH) suppression. The effects were studied on GH secretion (in response to growth hormone releasing factor and sleep) of mazindol 2 mg daily for 3 months in five boys with DMD. No consistent change was found following mazindol therapy. Adverse effects were noted in all the boys which may preclude long term use of mazindol in DMD.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1988 PMID： 3221222 PMCID： PMC1032773 DOI： 10.1136/jnnp.51.12.1551

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

18 in total

1. Conchotome and needle percutaneous biopsy of skeletal muscle.

Authors: P Dietrichson; J Coakley; P E Smith; R D Griffiths; T R Helliwell; R H Edwards
Journal: J Neurol Neurosurg Psychiatry Date: 1987-11 Impact factor: 10.154

2. Effect of anorexiant drugs on growth hormone secretion in obese children.

Authors: A Baritussio; G Enzi; G Rigon; M Molinari; E M Inelmen; G Crepaldi
Journal: Pharmacol Res Commun Date: 1978-06

3. Techniques for studying free radical damage in muscular dystrophy.

Authors: M J Jackson; D A Jones; R H Edwards
Journal: Med Biol Date: 1984

4. Potential uses of human pancreatic growth hormone-releasing factor 1-44 amide.

Authors: P E Belchetz; S F Weldon; J C Davis; M J Diver; C S Smith; F Harris
Journal: Clin Endocrinol (Oxf) Date: 1984-08 Impact factor: 3.478

5. Unexpected differences between mazindol and its homologs on biochemical and behavioral responses.

Authors: R E Heikkila; F S Cabbat; L Manzino; R G Babington; W J Houlihan
Journal: J Pharmacol Exp Ther Date: 1981-06 Impact factor: 4.030

6. Acute effects of mazindol on the secretion of ACTH, beta-lipotropin, beta-endorphin and cortisol in man.

Authors: K Sekiya; T Okajima; K Kato; H Ibayashi
Journal: Endocrinol Jpn Date: 1984-10

7. Weight reduction in boys with muscular dystrophy.

Authors: R H Edwards; J M Round; M J Jackson; R D Griffiths; M F Lilburn
Journal: Dev Med Child Neurol Date: 1984-06 Impact factor: 5.449

8. Human growth hormone and estrogens in boys with Duchenne muscular dystrophy.

Authors: S B Chyatte; D Rudman; J H Patterson; G G Gerron; I O'Beirne; J Barlow; A Jordan; J S Shavin
Journal: Arch Phys Med Rehabil Date: 1973-06 Impact factor: 3.966

9. Sleep-induced growth hormone release--evaluation of a simple test for clinical use.

Authors: J M King; D A Price
Journal: Arch Dis Child Date: 1983-03 Impact factor: 3.791

10. Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy.

Authors: P J Collipp; J Kelemen; S Y Chen; M Castro-Magana; M Angulo; A Derenoncourt
Journal: J Med Genet Date: 1984-08 Impact factor: 6.318

4 in total

4. Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs.

Authors: Daniele Parisi; Melissa F Adasme; Anastasia Sveshnikova; Sarah Naomi Bolz; Yves Moreau; Michael Schroeder
Journal: Comput Struct Biotechnol J Date: 2020-04-13 Impact factor: 7.271